News stories about SUMMIT THERAPEU/S (NASDAQ:SMMT) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. SUMMIT THERAPEU/S earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.7630690727861 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- SUMMIT THERAPEU/S (SMMT) Given a $20.00 Price Target at HC Wainwright (americanbankingnews.com)
- Analysts Expect SUMMIT THERAPEU/S (SMMT) Will Announce Quarterly Sales of $6.48 Million (americanbankingnews.com)
- SUMMIT THERAPEU/S (SMMT) Issues Earnings Results (americanbankingnews.com)
- Sales of new diesel cars fall by almost a quarter in May (ft.com)
- -$0.76 EPS Expected for SUMMIT THERAPEU/S (SMMT) This Quarter (americanbankingnews.com)
Several equities analysts have weighed in on SMMT shares. Zacks Investment Research upgraded shares of SUMMIT THERAPEU/S from a “sell” rating to a “hold” rating in a research report on Saturday, April 7th. HC Wainwright set a $20.00 price objective on shares of SUMMIT THERAPEU/S and gave the stock a “buy” rating in a research report on Wednesday, April 18th. Needham & Company LLC lowered their price objective on shares of SUMMIT THERAPEU/S from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, April 12th. BTIG Research started coverage on shares of SUMMIT THERAPEU/S in a research report on Tuesday, February 13th. They set a “buy” rating and a $33.00 price objective on the stock. Finally, ValuEngine upgraded shares of SUMMIT THERAPEU/S from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $25.38.
Shares of SUMMIT THERAPEU/S stock traded down $0.55 on Thursday, hitting $12.86. 1,066 shares of the company traded hands, compared to its average volume of 29,250. SUMMIT THERAPEU/S has a 12-month low of $8.80 and a 12-month high of $16.86. The stock has a market cap of $183.57 million, a P/E ratio of -17.13 and a beta of 0.80.
SUMMIT THERAPEU/S (NASDAQ:SMMT) last posted its quarterly earnings results on Tuesday, June 5th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.21. SUMMIT THERAPEU/S had a negative net margin of 33.36% and a negative return on equity of 95.06%. The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $6.48 million. research analysts anticipate that SUMMIT THERAPEU/S will post -2.46 earnings per share for the current year.
SUMMIT THERAPEU/S Company Profile
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with MarketBeat.com's FREE daily email newsletter.